Test Price
2,800 AEDโ Home Collection Available
KCNJ5 Gene Hyperaldosteronism Type III Genetic Test (NGS) โ DNA Labs UAE
Executive Summary & Core Metrics
Clinical Summary: This NGS-based genetic test detects pathogenic variants in the KCNJ5 gene causative of familial hyperaldosteronism type III (FH-III), enabling precision diagnosis and targeted management of early-onset hypertension and electrolyte dysregulation. The test is processed in our CAP-accredited molecular laboratory with 99.9% diagnostic sensitivity.
- Diagnostic Accuracy: 99.9% Sensitivity & Specificity โ ISO 15189:2022 & CAP-Accredited NGS Workflow.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM โ 11 PM).
- Clinical Guidance: Post-Test Telephonic Result Interpretation by a Consultant Medical Genetics specialist.
- Insurance Support: Direct Billing Verification via WhatsApp +971 54 548 8731.
- Regulatory Compliance: Full adherence to UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 on Health ICT.
Test Overview & Methodology
The KCNJ5 gene encodes the inwardly rectifying potassium channel Kir3.4, which plays a critical role in adrenal zona glomerulosa cell membrane potential and aldosterone secretion. Pathogenic gain-of-function mutations in KCNJ5 lead to constitutive aldosterone production, autonomous electrolyte imbalance, and familial hyperaldosteronism type III. This test employs next-generation sequencing (NGS) to interrogate all coding exons and flanking intronic regions of KCNJ5 with >100ร mean depth of coverage, providing single-nucleotide and small indel variant resolution essential for definitive genetic subtyping.
| Feature | KCNJ5 NGS Genetic Test | Closest Alternative (Aldosterone/Renin Ratio) |
|---|---|---|
| Precision | Full gene sequencing with variant-level resolution; identifies causative mutation | Biochemical screening only; cannot differentiate genetic subtype |
| Methodology | Next-Generation Sequencing (NGS) โ Illumina platform | Immunoassay or LC-MS/MS; no DNA analysis |
| Turnaround Time | 21โ28 Days (3โ4 Weeks) | 1โ3 Days |
| Diagnostic Utility | Confirms FH-III, guides targeted medical therapy and family cascade screening | Screens for primary aldosteronism; requires confirmatory adrenal venous sampling |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh โ Consultant Medical Genetics (DHA Registration ID: 9294403) โ shares, โA definitive KCNJ5 diagnosis transforms management from empirical antihypertensive polypharmacy to targeted therapy such as mineralocorticoid receptor antagonists or, in selected cases, unilateral adrenalectomy. However, results must always be interpreted alongside the full clinical phenotype, electrolyte profile, and three-generation family pedigree. Genetic counselling before and after testing is essential.โ
Advisory & Pre-Test Recommendations
Consult your referring physician before discontinuing any prescribed antihypertensive or potassium-modifying medication. Pre-test genetic counselling to construct a detailed family pedigree is strongly recommended. Have your complete clinical history, prior biochemical results (aldosterone, renin, potassium), and imaging reports ready for correlation.
Informed Consent: Per Federal Decree-Law No. 4 of 2016 on Medical Liability, written informed consent must be obtained prior to genetic testing. For minors, consent must be provided by a parent or legal guardian.
Exclusion Criteria & Emergency Red Flags
- Exclusion โ Hematologic Interference: Known clonal hematopoiesis of indeterminate potential (CHIP) or recent blood transfusion (<2 weeks) may confound germline NGS analysis on whole blood. A buccal swab or extracted DNA from an archival source may be required.
- Exclusion โ Informed Consent: Individuals unable to provide informed consent, or minors without a responsible caregiver to provide legal consent, are excluded until appropriate consent is secured.
- Emergency Red Flag โ Severe Hypokalemia: Serum potassium <3.0 mmol/L accompanied by cardiac arrhythmia, muscle weakness, or paralysis requires immediate emergency medical intervention.
- Emergency Red Flag โ Hypertensive Crisis: Blood pressure >180/120 mmHg with neurological symptoms (headache, visual disturbance, seizure) warrants urgent hospital evaluation.
- Important Disclaimer: This genetic test is a confirmatory diagnostic tool and is not a substitute for acute medical management of electrolyte or haemodynamic emergencies.
Patient FAQ & Clinical Guidance
1. What is the KCNJ5 genetic test and why is it performed?
This targeted NGS test identifies disease-causing mutations in the KCNJ5 gene responsible for familial hyperaldosteronism type III (FH-III). The result confirms the genetic subtype of primary aldosteronism, enabling personalized therapy โ for example, targeted use of mineralocorticoid receptor antagonists versus surgical referral โ and allows cascade screening of at-risk family members.
2. How is the sample collected and when will I receive my results?
The test requires 3โ5 mL of whole blood in an EDTA tube, a dried blood spot on an FTA card, or 1 ยตg of high-quality extracted genomic DNA. Our VIP Mobile Phlebotomy service can collect the sample at your home or office between 8 AM and 11 PM, using a temperature-controlled cold-chain transport. Results are reported within 21โ28 days (3โ4 weeks) from sample receipt in the laboratory.
3. Will my health insurance cover this test and how is my genetic data protected?
Our team can verify your insurance coverage and direct billing eligibility via WhatsApp at +971 54 548 8731. Your genetic and personal data are handled in strict compliance with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 on Health ICT. Genetic information is encrypted, access-controlled, and used solely for diagnostic and clinical purposes with your explicit consent.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance: DNA Labs UAE operates under the regulatory framework of the Dubai Healthcare City Authority (DHCA) and adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for the collection, processing, storage, and transfer of personal and genetic data. All genomic data is stored in ISO 27001-certified secure servers with role-based access controls and full audit logging. In accordance with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, electronic health records and genetic test results are transmitted through encrypted channels. Your data is retained only for the duration required by UAE health information regulations and is never shared with third parties without your explicit, written consent.
Clinical & Logistical Metadata
| Test Name | KCNJ5 Gene Hyperaldosteronism Type III Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21โ28 Days (3โ4 Weeks) from sample receipt |
| Sample Type / Matrix | Whole blood (EDTA, 3โ5 mL), FTA card dried blood spot, or extracted genomic DNA (โฅ1 ยตg) |
| Methodology Used | Next-Generation Sequencing (NGS) โ Full gene coding regions & flanking intronic boundaries, Illumina platform, โฅ100ร mean depth |
| ICD-10-CM Code | E26.09 |
| LOINC Code | 94802-9 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 โ Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians